This article has Open Peer Review reports available.
Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway
© The Author(s). 2016
Received: 27 August 2015
Accepted: 27 October 2016
Published: 8 November 2016
Tumor suppressive let-7 miRNAs are universally down-regulated in human hepatocellular carcinoma (HCC) versus normal tissues; however, the roles and related molecular mechanisms of let-7 in HCC stem cells are poorly understood.
We examined the inhibitory effect of let-7 miRNAs on the proliferation of MHCC97-H and HCCLM3 hepatic cancer cells by using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, which was further confirmed by apoptosis and cell cycle studies. The sphere-forming assay was used to study the effects of let-7a on stem like cells. Through western blot, immunofluorescence and the luciferase-reporter assay, we explored the activity of epithelial-mesenchymal transition (EMT) signaling factors in HCC cells. qRT-PCR was applied to detect miRNA expression levels in clinical tissues.
Let-7a effectively repressed cell proliferation and viability, and in stem-like cells, also let-7a decreased the efficiency of sphere formation.in stem-like cells. The suppression of EMT signaling factors in HCC cells contributed to let-7’s induced tumor viability repression and Wnt activation repression. Besides, Wnt1 is critical and essential for let-7a functions, and the rescue with recombinant Wnt1 agent abolished the suppressive roles of let-7a on hepatospheres. In clinical HCC and normal tissues, let-7a expression was inversely correlated with Wnt1 expression.
Let-7 miRNAs, especially let-7a, will be a promising therapeutic strategy in the treatment of HCC through eliminating HCC stem cells, which could be achieved by their inhibitory effect on the Wnt signaling pathway.
Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies worldwide, being recognized as the third leading cause of cancer-related deaths [1, 2]. HCC is the fifth most common malignancy in men and the seventh among women . The incidence of HCC depends on geography, and most of the burden is in developing countries, occurred with hepatitis. The situation is more severe in China, with poorer 5-year survival . The tumorigenesis of HCC is a multistage process including noncoding and protein-coding genes. MiRNAs are found to be deregulated in most malignancies, affecting carcinogenesis, progression, metastasis and tumor recurrence. In HCC, it has been reported that aberrant expression of let-7 miRNAs contributed to the development and progression of HCC [5, 6].
Research has indicated that some miRNAs may function as oncogenes when up-regulated in HCC; to the contrary, the down-regulated miRNAs suggested them as tumor suppressors [7, 8]. Functioning as tumor suppressors, let-7 miRNAs were found to repress Ras, Bcl-xl, MAPK, c-Myc, cyclin D1 and other oncogenes in HCC [8, 9]. Wnt1 stimulates the Wnt/β-catenin/TCF pathway, leading to different cell fates, and then regulating the transcription of many downstream genes which contain the TCF/LEF1 motif, affecting biological functions and the maintenance of self-renewal of cancer stem cells (CSCs) [10–12]. However, there is no research focused on the relationship between let-7 and the Wnt signaling pathway.
Tumors consist of cells with heterogeneity, with different characteristics, and the CSCs are demonstrated to be steady and stable through clinical chemo-radiotherapy, due to the slow cell cycles and low proliferative ability, contributing to tumor relapse and occurrence of resistance [8, 13]. Therefore, treatments targeting these silent CSCs will show great potential in eliminating the tumor group entirely, helping to overcome resistance to therapy and recurrence of the tumor. However, the underlying mechanism by which let-7 works to inhibit CSCs in HCC remains largely unknown.
Cell culture, transfection and infection
MHCC97-H and HCCLM3 human HCC cells were purchased from ATCC and maintained at the central laboratory of the Qilu Hospital of Shandong University. The cells are cultured in DMEM medium (Invitrogen, USA), containing 10 % fetal bovine serum (FBS), 1 % penicillin and 1 % streptomycin (Invitrogen, USA). The spheres (hepatospheres) were cultured in DMEM/Ham’s F-12 medium compounded with 10 ng/ml epidermal growth factor, 10 ng/ml human basic fibroblast growth factor, 4 μg/ml insulin, 1 % penicillin and 1 % streptomycin (Invitrogen, USA). Oligonucleotides encoding mature let-7a/b/c/d/e/f/g/i miRNAs and miRNA-LSC1 were synthesized by Invitrogen and cloned into the lentiviral vector lentilox3.7 (pLL3.7). SiRNAs targeting Wnt1were synthesized and purchased from GenePharma Inc. (Shanghai, China). Transfections were performed using Lipofectamine 2000 (Invitrogen, USA), and the siRNAs were added the second days after cells were plated. Transiently transfected HCC cells were harvested 48 h post-transfection.
Reverse transcription PCR and real-time PCR
Total RNA was isolated from fresh clinical specimen using TRIzol® Reagent (Invitrogen, USA) following mechanical tissue homogenization, or from or cultured cells using Trizol reagent after treatment with 5 μg/ml puromycin for 48 h. Approximately 1 μg of RNA was reverse-transcribed to single strand cDNA using PrimeScript RT Master Mix (Takara Biotechnology, China). The real-time PCR was conducted in a total volume of 25 μl as previously reported [7, 14]. The cycle threshold (Ct) was automatically calculated by iQ™-5 Optical Module software (Bio-rad, USA). The relative expression of let-7 family members was normalized to U6 expression, and then calculated using the formula 2−ΔΔCt method, versus the scramble control.
Sphere formation assays
The spheres formation assay is often used to enrich stem-like cells, being are used to isolate and expand population enriched in CSCs [15–18]. Cells of different groups were seeded in ultra-low adherent-conditioned plates (Corning, USA) to test their ability of forming primary spheres, in the presence of puromycin. In total, 12,000 cells were seeded per 6 cm plate. On day 9, cell sphere number of spheres was counted using an inverted microscope, a sphere was defined as contaning more than 10 cells. The sphere-forming efficiency was calculated as the percentage of counted spheres versus seeded cells . Spheres of different groups were disaggregated, and 12,000 cells were then re-suspended per 6 cm plate to test their self-renewal ability.
Immunofluorescence and IHC
Cells were seeded on glass chamber slides for 24 h, and then fixed by 10 % formalin for 15 min. Antigens were blocked with 2 % normal goat serum (ab7481, Abcam, USA), cells werethen incubated with the β-catenin antibody for 1 h in PBS, and then incubated with Alexa Fluor® 488 (Life technologies, USA) for 30 min, washed in PBS, incubated for 10 min with 2 μg/ml of Hoechst 33342 (Life technologies, USA), and washed with PBS again. For IHC, the paraffin tissues were rehydrated in an alcohol gradient and then were rinsed in deionized water. Endogenous peroxidase activity was blocked using a 0.03 % hydrogen peroxide solution. 1:200 IHC-TekTM Antibody Diluent (IW-1000, Ellicott City, MD, USA) was used to reduce background staining. The section was then incubated with 1 μg/ml ab16051 for 1 h at room temperature and detected using an HRP, DAB was used as the chromogen.
Flow cytometry analysis
The propidium iodide (PI) and Annexin V-FITC (Green) kits were obtained from BD Biosciences (San Jose, CA). Cells of different groups were collected and trypsinized into a single cell, and then washed twice with PBS. All cells were resuspended in 500 μl binding buffer respectively, and 5 μl of Annexin V-FITC and 10 μl of PI were added. The mixture was gently vortexed and then incubated for 15 min at room temperature in the dark. The cells were analyzed by FACSAria cytometry within 1 h of incubation using BD FACSuite Software. For cell cycle analysis, 5 × 105 cells were collected and washed twice with PBS. Cells were fixed with ice-cold 70 % ethanol at 4 °C for 24 h. Before detection, the fixed cells were stained with PI for 30 min at 37 °C, followed by FACSAria cytometry. All tests were performed in triplicate. Cell cycle analysis of DNA content was performed using MultiCycle software. Instrument Setup instructions were followed as presenteding online documentation: https://www.bdbiosciences.com/documents/BD_FACSVerse_Apoptosis_Detection_AppNote.pdf.
The TCF/lymphoid enhancer factor luciferase reporter (TOP) and its negative control (FOP) plasmids were obtained from Upstate Biotechnology (NY, USA). Cells were plated at 30–40 % confluence in 24-well plates 16 h prior to transfection by using FuGENE 6 (Roche, USA) .
Let-7 and Wnt1 expression in clinical tissues
To explore the role of let-7a in HCC, we first collected specimens from 58 patients, who underwent surgery at the Department of General Surgery, the Second Hospital of Jilin University from June 2008 to November 2013. Of the samples collected, 20 slides were prepared for IHC using a Wnt 1 (1:200; sc-6280, Santa Cruz, USA). All of the patients were diagnosed and confirmed by pathological examination. No preoperative chemotherapy or radiotherapy was performed in any of these patients. Specimens were stored in liquid nitrogen. This study was conducted under the supervision of the Ethical Board of Jilin University.
All data were obtained from at least three independent experiments, are expressed as mean ± SD and were analyzed by Student’s T-test and χ 2 test using SPSS for Windows version 16.0 (IBM, USA) and Excel 2010 (Microsoft, USA).
The function of let-7 miRNAs in HCC cells
Overexpressing let-7a induced apoptosis and cell cycle arrest of HCC cells
To examine whether the enforced let-7a could induce cell apoptosis and cell cycle arrest, both MHCC97-H and HCCLM3 cell lines were subjected to Flow cytometry analysis. We found that both of these HCC cell lines exhibited higher apoptosis ratios (T-test, p < 0.01, Fig. 2b). Let-7a also induced cell cycles arrest at G1 (T-test, p < 0.01, Fig. 2c). Representative images of apoptosis and cell cycle are shown in Fig. 2d-e.
Let-7a suppressed the sphere formation efficiency of HCC cells
Overexpressing let-7a suppressed the EMT factors of HCC cells and Wnt signaling pathway of HCC stem-like cells
Decreased Wnt1 is required for let-7a-induced renewal inhibition of hepatospheres
Let-7a sensitized HCC stem-like cells to cis-platinum-induced self-renewal inhibition
The loss of let-7a was related to the occurrence and progress of HCC
Let-7 is a family consisting of 13 members located on nine different chromosomes whose expression is usually lost, reduced, or deregulated in most human malignancies . Growing evidence suggests that the restoration of let-7 expression effectively repressed cell proliferation, invasion, metastasis, and resistance to therapy. The findings of let-7 repression on CSC self-renewal indicated that let-7 restoration may be a useful therapeutic option in HCC and stem-like cells, which was more crucial for curing the cancer [8, 22–24]. Recent studies found that cholesterol-conjugated let-7a inhibited cell proliferation, growth, and metastasis, and mainly functioned in the cytoplasm through directly reaching HCC orthotropic tumors . What’s more, the therapeutic trial of let-7 mimics showed suppressed effects on tumor growth in pre-clinical studies . Especially, nanoparticle-based let-7 replacement therapy had been successfully applied in vivo, together with other delivery methods, including lentivirus-mediated pre–let-7 s, adenovirus-mediated hairpin sequences of mature let-7, cationic liposome–mediated pre–let-7, and electroporation of synthetic let-7 [8, 26].
In this study, we show that overexpressing let-7a exerted inhibitory effects on HCC, consistent with previously published results for other malignancies [27, 28]. EMT inducers, including Snail, Slug, Twist1, ZEB1 and ZEB2, suppress the expression of adherence proteins to induce cellular malignancies. EMT is a major mechanism for cancer generation, metastasis and progression , which ultimately promote the growth of tumor bulk and cell proliferation, and during the EMT process, CSCs are generated . We found that increased let-7a could inhibit sphere formation efficiency through alleviating EMT via down-regulating N-cadherin and Snail in HCC cells. In HCC stem-like cells, overexpressing let-7a inhibited the Wnt1/Frizzled/β-catenin signaling pathway, which was involved in maintaining the self-renewal ability of stem cells. We further identified that repressed Wnt1/Frizzled/β-catenin signaling in a CSC-enriched population was attributed to enforced let-7 and let-7 enhanced cis-platinum functions, helping to inhibit the self-renewal of stem-like cells. Our results suggest that overexpression of let-7a could be used as a therapeutic agent and prognostic indicator in the management of HCC against Wnt activation, and help to understand the mechanisms through which let-7 regulated HCC stem cells.
Let-7 functions are detailed explored in many kinds of tumors, and let-7 acted through post-transcriptional regulations of the targeted genes . However, the roles of let-7 in HCC stem-like cells are less involved. For the first time, we identified the let-7 controlled Wnt signaling activity, which was accused for maintaining of cell pluripotency. Wnt/β-catenin transactivation of let-7 in breast cancer further suggested the regulatory roles of let-7 in stem cells’ regulations . Overall, our results suggest that overexpression of let-7a could be used as a therapeutic agent and prognostic indicator in the management of HCC via repression of Wnt signaling activation in stem cells, and to help understand the mechanisms through which let-7 regulates HCC stem cells.
We appreciate the great help of the central laboratory and the center of translational medicine of the Qilu Hospital of Shandong University. We also appreciated very much for the help of Shou-Ching Tang (Georgia Regents University Cancer Center, Augusta, GA 30912 USA, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China), who worked hard at language polishing, editing and consent resembling, which did not match the criteria for authorship of BMC Cancer.
This study was supported by the National Natural Science Foundation of China (81100323), the Fundamental Research Funds of Shan Dong University (Qilu Hospital Research Project, 2014QLKY18), and the Project Fund of Techpool (UF201330).
Availability of data and materials
All data of this paper belonged to the center of translational medicine, the Qilu Hospital of Shandong University, and could not be shared as public data. The data could be shared personally after negotiation with signed document. All the data will be applied for answering and finishing the National Grant. If anyone have trouble in getting certain materials listed in this study, the authors could be contacted via email listed below. Supportive methods were involved in “Supplemental data”.
BJ: Conception and design, Financial support, Administrative support, Provision of study material or patients, Coordination of experiments, Manuscript writing, Statistical analysis. WW: Immunohistochemistry staining, Sphere-formation assays, Collection and assembly of data. XM: Conception and design, Manuscript writing. GD: Quantitative Real-time PCR, Immunohistochemistry staining, Luciferase assay, Transduction of lentiviral vectors. JL: Cell culture, Western blot, Sphere-formation assays. SZ: Cell culture, Western blot, Luciferase assay, Sphere-formation assays. BZ: Provision of study material or patients, Manuscript writing. ZF: Western blot, Collection and assembly of data. All scholars contributing to this project are all listed as co-authors, and all co-authors are agreed of publishing this paper generated from our research. All authors read and approved the final manuscript.
The authors declare that they have no competing interest.
Consent for publication
Ethics approval and consent to participate
Written informed consent was obtained according to the guidelines approved by the Institutional Review Board. This study is approved by the Ethics Committee of the Qilu Hospital of Shandong University, and consent to publish has been obtained from all participants. All patients whose cancer tissues were collected and used agreed to participate in this study, and informed consents together with the consents for publication were obtained and kept in the Department of Ethics Committee. No individual patient data was acquired in this study, and the private information of individual patient are not and will not be displayed.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.View ArticlePubMedGoogle Scholar
- Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–10. doi:10.1093/carcin/bgp263.View ArticlePubMedGoogle Scholar
- El-Serag HB. Hepatocellular Carcinoma. N Engl J Med. 2011;365(12):1118–27. doi:10.1056/NEJMra1001683.View ArticlePubMedGoogle Scholar
- Wu HC, Santella R. The Role of Aflatoxins in Hepatocellular Carcinoma. Hepat Mon. 2012;12(10 HCC):e7238. doi:10.5812/hepatmon.7238.View ArticlePubMedPubMed CentralGoogle Scholar
- Chu R, Mo G, Duan Z, Huang M, Chang J, Li X, et al. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal. 2014;12:45. doi:10.1186/s12964-014-0045-y.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhu Z, Zhang X, Wang G, Zheng H. Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon. 2014;14(8), e18672. doi:10.5812/hepatmon.18672.PubMedPubMed CentralGoogle Scholar
- Sun X, Qin S, Fan C, Xu C, Du N, Ren H. Let-7: a regulator of the ERalpha signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep. 2013;29(5):2079–87. doi:10.3892/or.2013.2330.PubMedGoogle Scholar
- Sun X, Jiao X, Pestell TG, Fan C, Qin S, Mirabelli E, et al. MicroRNAs and cancer stem cells: the sword and the shield. Oncogene. 2014;33(42):4967–77. doi:10.1038/onc.2013.492.View ArticlePubMedGoogle Scholar
- Sun X, Tang S-C, Xu C, Wang C, Qin S, Du N, et al. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1. J Cell Mol Med. 2015;19(6):1357–65. doi:10.1111/jcmm.12522.View ArticlePubMedPubMed CentralGoogle Scholar
- Choi AR, Park JR, Kim RJ, Kim SR, Cho SD, Jung JY, et al. Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer. Biochem Biophys Res Commun. 2012;425(2):436–42. doi:10.1016/j.bbrc.2012.07.120.View ArticlePubMedGoogle Scholar
- Katoh M, Katoh M. WNT Signaling Pathway and Stem Cell Signaling Network. Clin Cancer Res. 2007;13(14):4042–5. doi:10.1158/1078-0432.ccr-06-2316.View ArticlePubMedGoogle Scholar
- He B, Jablons DM. Wnt Signaling in Stem Cells and Lung Cancer. In: Wiestler OD, Haendler B, Mumberg D, editors. Cancer Stem Cells. Springer Series on Biofilms: Springer Berlin Heidelberg; 2007. p. 27–58.Google Scholar
- Rupaimoole R, Han HD, Lopez-Berestein G, Sood AK. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011;30(6):368–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun X, Jiang S, Liu J, Wang H, Zhang Y, Tang SC, et al. MiR-208a stimulates the cocktail of SOX2 and beta-catenin to inhibit the let-7 induction of self-renewal repression of breast cancer stem cells and formed miR208a/let-7 feedback loop via LIN28 and DICER1. Oncotarget. 2015;6(32):32944–54. doi:10.18632/oncotarget.5079.PubMedPubMed CentralGoogle Scholar
- Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, et al. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. 2012;131(12):2808–19. doi:10.1002/ijc.27595.View ArticlePubMedGoogle Scholar
- Piscitelli E, Cocola C, Thaden F, Pelucchi P, Gray B, Bertalot G et al. Culture and Characterization of Mammary Cancer Stem Cells in Mammospheres. In: Rich IN, editor. Stem Cell Protocols. Methods in Molecular Biology: Springer New York; 2015. p. 243–62.Google Scholar
- Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, et al. Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin. PLoS One. 2013;8(10), e77281. doi:10.1371/journal.pone.0077281.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang R, Lv Q, Meng W, Tan Q, Zhang S, Mo X, et al. Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors. J Thorac Dis. 2014;6(6):829–37. doi:10.3978/j.issn.2072-1439.2014.03.38.PubMedPubMed CentralGoogle Scholar
- Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, et al. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell. 2012;11(3):401–14. doi:10.1016/j.stem.2012.06.007.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou J, Wang C, Wang Z, Dampier W, Wu K, Casimiro MC, et al. Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proc Natl Acad Sci. 2010;107(15):6864–9. doi:10.1073/pnas.1002746107.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1):F19–36. doi:10.1677/erc-09-0184.View ArticlePubMedGoogle Scholar
- Rothschild S. microRNA therapies in cancer. Mol Cell Ther. 2014;2(1):7.View ArticlePubMedPubMed CentralGoogle Scholar
- Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. Mol Ther. 2013;21(1):185–91. http://www.nature.com/mt/journal/v21/n1/suppinfo/mt2012180s1.html.View ArticlePubMedGoogle Scholar
- Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, et al. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res. 2014;20(17):4499–510. doi:10.1158/1078-0432.ccr-14-0348.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu YM, Xia Y, Dai W, Han HY, Dong YX, Cai J, et al. Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy. BMC Cancer. 2014;14:889. doi:10.1186/1471-2407-14-889.View ArticlePubMedPubMed CentralGoogle Scholar
- Barh D, Malhotra R, Ravi B, Sindhurani P. Microrna let-7: an emerging next-generation cancer therapeutic. Curr Oncol. 2010;17(1):70–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.View ArticlePubMedGoogle Scholar
- Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11–26. http://www.nature.com/nrc/journal/v13/n1/suppinfo/nrc3419_S1.html.View ArticlePubMedGoogle Scholar
- Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat Cell Biol. 2014;16(3):268–80. doi:10.1038/ncb2910.View ArticlePubMedGoogle Scholar
- Sterenczak KA, Eckardt A, Kampmann A, Willenbrock S, Eberle N, Langer F, et al. HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma. BMC Cancer. 2014;14:694. doi:10.1186/1471-2407-14-694.View ArticlePubMedPubMed CentralGoogle Scholar
- Cai WY, Wei TZ, Luo QC, Wu QW, Liu QF, Yang M, et al. The Wnt-beta-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J Cell Sci. 2013;126(Pt 13):2877–89. doi:10.1242/jcs.123810.View ArticlePubMedGoogle Scholar